Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia
W Jurczak, N Elmusharaf, CP Fox… - Therapeutic …, 2023 - journals.sagepub.com
Background: Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
have limited treatment options. Ceralasertib, a selective ataxia telangiectasia and Rad-3 …
have limited treatment options. Ceralasertib, a selective ataxia telangiectasia and Rad-3 …
[HTML][HTML] Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm …
AP Kater, Ö Arslan, F Demirkan, Y Herishanu… - The Lancet …, 2024 - thelancet.com
Background Most patients with chronic lymphocytic leukaemia progress after treatment or
retreatment with targeted therapy or chemoimmunotherapy and have limited subsequent …
retreatment with targeted therapy or chemoimmunotherapy and have limited subsequent …
High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
G Chiodin, S Drennan, EA Martino… - Blood …, 2022 - ashpublications.org
Chronic lymphocytic leukemia (CLL) cells have variably low surface IgM (sIgM)
levels/signaling capacity, influenced by chronic antigen engagement at tissue sites. Within …
levels/signaling capacity, influenced by chronic antigen engagement at tissue sites. Within …
[HTML][HTML] Systematic Evaluation of Antigenic Stimulation in Chronic Lymphocytic Leukemia: Humoral Immunity as Biomarkers for Disease Evolution
A Landeira-Viñuela, M Alcoceba-Sanchez… - Cancers, 2023 - mdpi.com
Simple Summary Clonal B cell expansion in chronic lymphocytic leukemia may be triggered
by persistent antigenic stimulation. Therefore, studying the dynamics of the humoral …
by persistent antigenic stimulation. Therefore, studying the dynamics of the humoral …
[HTML][HTML] Time for a new prognostic score in CLL?
F Forconi - Blood, 2024 - eprints.soton.ac.uk
In this issue of Blood, Langerbeins et al 1 evaluated the prognostic value of the current
Chronic Lymphocytic Leukemia International Prognostic Index (CLL-IPI) using a pooled …
Chronic Lymphocytic Leukemia International Prognostic Index (CLL-IPI) using a pooled …
Caracterización sistemática mediante proteómica funcional de la disfunción de la respuesta inmune en Leucemia Linfocítica Crónica
A Landeira Viñuela - 2023 - gredos.usal.es
[ES] El objetivo general es establecer una estrategia sistemática que permita la
caracterización multi-ómica para la evaluación de perfiles proteicos diferenciales y desvele …
caracterización multi-ómica para la evaluación de perfiles proteicos diferenciales y desvele …